AI Science Tracker

MIT

16 discoveries from 2020 to 2026

Discoveries

Human-in-the-loop AI copilot improves topology-optimized structure design

MIT’s November 13, 2026 announcement describes a machine-learning copilot that flags regions for human edits during topology optimization. It reports improved manufacturability and buckling-load performance, but the reviewed announcement identifies no separate structural discovery or experimentally demonstrated new structure beyond testing the design workflow. Synthetic feedback training and limited thickening/thinning edits are acknowledged. The full journal paper was not assessed. The publisher abstract specifies improved manufacturability or a 39% linear-buckling-load improvement; it does not assign 39% to both metrics. The paper was published November 10; this entry represents the November 13 announcement.

Technology: Human-in-the-loop AI copilot with topology optimization (machine-learning region-flagging model)

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Computational topology-optimization workflow demonstrations; no separate structural finding established in reviewed scope.
  • Still unknown: Admission review pending: primary full results needed to distinguish a specific scientific/application result from general method validation. Existing supported claims may be retained with bounded scope, but do not mark source checked until admission is resolved.
  • AI role: A machine-learning model quickly identifies design regions a human would likely want to change, within a topology optimization workflow.

Evidence sources: https://news.mit.edu/2026/new-ai-copilot-helps-engineers-design-better-structures-1113 · https://www.nature.com/articles/s44172-026-00818-x

Needs source check · editorial details

The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Unrealistic emissions scenarios help AI climate models prepare for unfamiliar futures

MIT researchers with Imperial College London designed a small synthetic set of deliberately unrealistic emissions scenarios to train climate emulators, which normally need six to eight full Earth system model runs that each take months. The method needs only one model run, and the emulator predicted unseen scenarios and local pollutant-control effects where traditional emulators failed. It was validated with a simple climate model rather than a full Earth system model, and the article reports no quantitative accuracy metrics.

Technology: Climate emulator trained on optimized synthetic scenarios

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: An emulator trained on a small set of synthetic scenarios predicted unseen scenarios and a local pollutant-control effect where traditional emulators failed. The source says it was validated with a simple climate model.
  • Still unknown: The source says the method still needs testing on a full Earth system model scenario and on other climate model types; it does not say whether this has been done.
  • AI role: An optimization algorithm generated the synthetic training scenarios; an AI emulator was trained on them to predict climate outcomes.

Evidence sources: https://news.mit.edu/2026/new-research-could-lead-faster-trustworthy-ai-models-climate-prediction-1112

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: not linked in this catalog; this does not mean no paper exists.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

IRIS model reconstructs signaling histories of single cells

IRIS inferred signaling histories from gene activity after training on human stem-cell perturbations. The researchers used it to identify a signaling intervention predicted to encourage lung development and report experimental confirmation in mouse embryos. This summary is limited to MIT/Whitehead’s October 15, 2026 announcement, which explicitly dates the Nature Methods paper to September 8. The release supplies no quantitative accuracy metrics; proposed organoid and therapeutic uses are future applications.

Technology: IRIS (neural network with transfer learning)

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Inferred cell signaling histories and a lung-development prediction checked in mouse embryos, according to the institutional release.
  • Still unknown: Source checking does not establish independent confirmation. Review date: 2026-11-15.
  • AI role: IRIS learns consistent pathway fingerprints in gene activity across cell types, reconstructs signaling histories, and generated the lung-development prediction that was tested in mouse embryos.

Evidence sources: https://news.mit.edu/2026/ai-model-decodes-language-cells-use-communicate-1015

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

A1: deep learning identifies an antibiotic candidate against gonorrhea

A screen of about six million compounds found candidates active against resistant Neisseria gonorrhoeae. A1 reduced bacteria in animal models, and proteomics, genetics, and biochemistry confirmed its target, alanine racemase. These are preclinical results, published in Science Translational Medicine.

Technology: Deep learning for molecule screening

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Phenotypic screen of 38,650 molecules trained a graph neural network, which screened about 6 million compounds; 213 were validated experimentally, 83 inhibited growth. Two hits were tested in vitro against multidrug-resistant strains, by proteomics (alanine racemase target), in a vagina-on-a-chip model and in a mouse vaginal infection model.
  • Still unknown: Not reported (the abstract describes the in vivo and organ-chip results as showing only early promise).
  • AI role: A graph neural network trained on phenotypic screening data, used to virtually screen the compound library before experimental validation.

Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1126/scitranslmed.ads4699&resultType=core&format=json · https://news.ki.se/ai-helps-identify-new-antibiotic-candidates-against-drug-resistant-gonorrhoea

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

MIT

First-principles neural network finds crystallization of fractional quantum Hall liquids

A self-attention neural-network wavefunction (MagNet), trained only by minimising the microscopic Hamiltonian of interacting electrons in a magnetic field, finds both topological liquid and electron-crystal ground states across a range of Landau-level mixing. The authors present it as a method that discovers correlated phases without assumptions. This is an arXiv preprint with computational results only, not yet checked experimentally or peer reviewed.

Technology: MagNet: self-attention neural-network variational wavefunction

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: A self-attention neural-network wavefunction trained only by minimising the microscopic Hamiltonian found topological liquid and electron-crystal ground states across Landau-level mixing; the abstract reports computational results only.
  • Still unknown: The page states no limitations and mentions no experimental checks; the arXiv page lists a PRX Intelligence journal reference, while the source record describes it as a preprint.
  • AI role: The MagNet self-attention neural network served as the variational wavefunction, trained by energy minimisation without labelled data.

Evidence sources: https://arxiv.org/abs/2602.03927

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review scope and date are not recorded; source checked does not establish full-text review.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

MIT

Enterololin: AI helps clarify an antibiotic and its mechanism

An AI screen of over 10,000 molecules identified enterololin, and DiffDock predicted its binding to LolCDE within minutes, confirmed by resistant E. coli mutants, RNA-seq, and CRISPR. The mechanism was clarified in about six months versus 18–24 with traditional methods. In mice, in Crohn's-like inflammation models, healing was faster than with vancomycin. Early stage; no human testing.

Technology: Machine-learning screening and DiffDock

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Enterololin was tested in mouse Crohn's-like inflammation models against vancomycin, with resistant mutant sequencing, RNA-seq and CRISPR knockdown used to clarify its mechanism.
  • Still unknown: The source states it is early-stage development, no human data are reported, and clinical trials are not yet started.
  • AI role: DiffDock predicted binding of enterololin to the LolCDE complex within minutes, guiding lab experiments on the mechanism.

Evidence sources: https://news.mit.edu/2025/ai-maps-how-new-antibiotic-targets-gut-bacteria-1003 · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41564-025-02142-0&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 28 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

MIT

Antibiotics designed with generative AI against gonorrhea and MRSA

Over 36 million possible compounds were screened computationally: candidate NG1 killed resistant Neisseria gonorrhoeae in a dish and in a mouse model, while DN1 cleared a MRSA skin infection in mice. Only 2 of 80 fragment candidates could be synthesized; these are preclinical results.

Technology: Generative AI for molecule design

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Generative models screened more than 10^7 chemical fragments in silico against N. gonorrhoeae or S. aureus, plus unconstrained design. Of 24 synthesized compounds, seven showed selective antibacterial activity; two leads reduced bacterial burden in mouse infection models.
  • Still unknown: Mouse results only; no human testing is stated. The paper's abstract was read, not the full text.
  • AI role: Genetic algorithms and variational autoencoders generated fragment-based and de novo compounds; researchers synthesized and tested selected compounds.

Evidence sources: https://www.cell.com/cell/abstract/S0092-8674(25)00855-4

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review date: 16 Nov 2026. Review scope: Original institutional announcement checked for the specific results, AI contribution and limitations cited in the antibiotic dossier or mathematical follow-up pilot. Full-paper reanalysis, external replication and an exhaustive follow-up search were not performed..

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 127 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

Directed relationships from this entry; they do not merge catalog counts.

  • 2020-02-halicin · extends: The source names this earlier screening result as program background for moving to de novo generative design. New compounds and experiments; not a clinical follow-up or replication of the earlier candidate. Source
  • 2023-05-abaucina · extends: The source names this earlier screening result as program background for moving to de novo generative design. New compounds and experiments; not a clinical follow-up or replication of the earlier candidate. Source
MIT

An autonomous platform speeds research on polymer mixtures

The platform tests up to 700 mixtures a day (96 at a time), guided by a genetic algorithm: hundreds of mixtures outperformed the individual components, and the best retained 73% enzyme activity, 18% more than the best component. Application is limited to enzyme thermal stability, replenishment is still manual; published in Matter.

Technology: Genetic algorithm with robotics

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: An autonomous platform tested up to 700 polymer mixtures a day, and the best mixtures retained 73% enzyme activity, 18% more than the best component, in a retrospective analysis of the results.
  • Still unknown: The source states application is limited to enzyme thermal stability and replenishment is still manual.
  • AI role: A genetic algorithm guided the choice of polymer mixtures tested by the robotic platform.

Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1016/j.matt.2025.102336&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: at percentile 90 of works of the same type, year and subfield (OpenAlex work metrics, 14 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

MIT

AI identifies semapimod against dormant bacteria

A machine-learning system selected semapimod, a known anti-inflammatory drug, for activity against dormant Gram-negative bacteria. MIT reports laboratory activity against E. coli and A. baumannii and an effect that sensitizes these bacteria to other antibiotics; the result is preclinical and does not demonstrate efficacy in patients.

Technology: Machine learning for compound screening

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Lab-only time-lapse microscopy of E. coli treated with semapimod showed activity against stationary-phase E. coli and A. baumannii and sensitization to other antibiotics.
  • Still unknown: The article states no limitations, no animal or patient testing is mentioned, and no drug combinations are named.
  • AI role: AI-based high-throughput screening of known drug compounds identified semapimod for antibiotic activity.

Evidence sources: https://news.mit.edu/2024/mit-scientists-are-using-artificial-intelligence-target-sleeper-bacteria-0408

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 59 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

MIT

A new class of antibiotic candidates against MRSA

A deep-learning model trained on about 39,000 compounds screened about 12 million commercial compounds; of about 280 purchased and tested, two from the same class reduced MRSA burden tenfold in two mouse models, with very low toxicity to human cells. Results from plates and mice; toxicity was partly predicted computationally.

Technology: Deep learning with chemical-structure explainability

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: About 283 compounds were bought and tested empirically; one structural class reduced bacterial burden in mouse skin and systemic thigh infection models, and cytotoxicity to human cells was measured.
  • Still unknown: The page does not list specific study limitations; next steps are chemical property analysis and potential clinical use.
  • AI role: Graph neural network ensembles trained on about 39,000 compounds with measured antibacterial and human-cell toxicity predicted both properties for about 12 million compounds and flagged candidates for purchase and testing.

Evidence sources: https://news.mit.edu/2023/using-ai-mit-researchers-identify-antibiotic-candidates-1220 · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41586-023-06887-8&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 538 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Abaucin: a targeted antibiotic against Acinetobacter baumannii

A model trained on about 7,500 compounds screened 6,680 new compounds in under two hours; of 240 tested in the laboratory, nine were antibiotics, including abaucin, which was effective against wound infections in mice. Activity is highly narrow (no effect on the other bacteria tested) and still preclinical.

Technology: Machine learning for compound screening

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: About 7,500 molecules were screened in vitro, a neural network predicted new compounds that were tested in the laboratory (about 240 tested, nine antibiotics), and abaucin controlled an A. baumannii infection in a mouse wound model.
  • Still unknown: The abstract states no explicit limitations; the press release says activity is highly narrow (no effect on the other bacteria tested) and the compound remains preclinical.
  • AI role: A neural network trained on screening results predicted structurally new compounds active against A. baumannii.

Evidence sources: https://news.mit.edu/2023/using-ai-scientists-combat-drug-resistant-infections-0525 · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41589-023-01349-8&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review date: 16 Nov 2026. Review scope: Original institutional announcement checked for the specific results, AI contribution and limitations cited in the antibiotic dossier or mathematical follow-up pilot. Full-paper reanalysis, external replication and an exhaustive follow-up search were not performed..

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 420 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships
  • same-team extension · 14 Aug 2025: MIT identifies halicin and abaucin as earlier screening results motivating generative design of new NG1/DN1 candidates. The later study does not establish clinical efficacy of these earlier candidates. Source. Recorded 16 Nov 2026.

Follow-up checked 16 Nov 2026 within scope: Bounded check of the original announcements cited by the events recorded here, including explicit links to later program work. This is not an exhaustive literature search or ongoing monitoring commitment..

Directed relationships from this entry; they do not merge catalog counts.

  • 2020-02-halicin · extends: The source explicitly traces this A. baumannii screening study to the earlier halicin program. Distinct candidate and experiment; not independent confirmation of halicin. Source

Sybil: lung-cancer risk prediction up to six years from a low-dose CT

The model predicts risk from a single CT with a six-year C-index of 0.75 (NLST), 0.81 (MGH) and 0.80 (CGMH), and a one-year ROC area between 0.86 and 0.94. Retrospective validation on three independent datasets; trained only on smokers, with prospective testing and testing in nonsmokers as next steps.

Technology: Sybil (neural network on CT scans)

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: The model was trained on NLST low-dose CT scans and validated on a held-out NLST set and two independent cohorts (MGH and CGMH), with six-year C-index 0.75, 0.81 and 0.80; the abstract describes no prospective testing.
  • Still unknown: The abstract states that future study is required to understand clinical applications; the press release says prospective testing and testing in nonsmokers are next steps.
  • AI role: A deep learning model predicts lung-cancer risk from a single low-dose chest CT.

Evidence sources: https://news.mit.edu/2023/ai-model-can-detect-future-lung-cancer-0120 · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1200/JCO.22.01345&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 332 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

MIT

Mirai: future breast cancer risk from mammograms

Mirai, trained on over 200,000 exams, was evaluated on hospital data from the United States, Sweden, and Taiwan. In a comparison of high-risk groups at Massachusetts General Hospital, it identified nearly twice as many future diagnoses as Tyrer-Cuzick; it does not demonstrate reduced mortality.

Technology: Deep learning on mammograms

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: Mirai was validated on held-out test sets from MGH, Karolinska and Chang Gung, and identified nearly twice as many future diagnoses as Tyrer-Cuzick in high-risk groups.
  • Still unknown: It does not use prior imaging and is still being validated in more diverse populations, and it does not show reduced mortality.
  • AI role: Deep learning predicted future breast cancer risk from mammograms.

Evidence sources: https://news.mit.edu/2021/robust-artificial-intelligence-tools-predict-future-cancer-0128 · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI%3A10.1126/scitranslmed.aba4373&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 320 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

MIT

Language models identify viral regions less prone to immune escape

Analysis of influenza, HIV, and coronavirus sequences identifies regions of surface proteins less likely to mutate to escape immune responses, including the S2 subunit of spike. These are computational leads for studying possible vaccine targets, not validated vaccines.

Technology: Protein-sequence language model

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: Language models trained on about 60,000 HIV, 45,000 influenza and 4,000 coronavirus sequences were checked against earlier findings on influenza and HIV; the SARS-CoV-2 analysis is described as not yet peer-reviewed.
  • Still unknown: Flagged SARS-CoV-2 sequences still need investigation, and it is unknown how fast SARS-CoV-2 mutates, so how long current vaccines stay effective is unclear.
  • AI role: Adapted language-model methods to viral protein sequences to predict surface regions more or less likely to enable immune escape, as candidate vaccine targets.

Evidence sources: https://news.mit.edu/2021/model-viruses-escape-immune-0114 · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1126/science.abd7331&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 383 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

MIT

A model analyzes coughs to detect COVID-19 infections

A model trained on volunteer recordings recognized 98.5% of coughs associated with confirmed infections in the test reported by MIT. This is an early result on data collected online, with health status also self-reported; it is not a diagnosis or prospective clinical validation.

Technology: Neural networks for audio

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: retrospective or benchmark
  • Tested: Model trained on 4,256 subjects and tested on 1,064 held-out subjects from web-collected cough recordings, with results validated against official COVID-19 test outcomes; sensitivity 98.5% and specificity 94.2% overall, but 83.2% specificity in asymptomatic subjects.
  • Still unknown: Not a diagnosis for symptomatic people and does not separate Covid from flu or asthma; status was self-reported; false-positive results for healthy participants not reported; app would need approval and a larger, more diverse dataset.
  • AI role: Neural networks trained on cough biomarkers (vocal cords, sentiment in speech, lung performance) combined with a muscular-degradation estimate to flag Covid-positive coughs.

Evidence sources: https://news.mit.edu/2020/covid-19-cough-cellphone-detection-1029 · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1109/OJEMB.2020.3026928&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review scope and date are not recorded; source checked does not establish full-text review.

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 609 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

MIT

Halicin: deep learning identifies an antibiotic

A model trained on about 2,500 molecules screened the roughly 6,000 compounds in the Broad Institute’s Drug Repurposing Hub and identified halicin, which killed many resistant bacteria in the lab and cleared A. baumannii infections in mice within 24 hours. Cell-culture and mouse results, not human studies; the mechanism remains preliminary.

Technology: Graph neural network for predicting antibacterial activity

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Bactericidal activity against a wide range of pathogens, including M. tuberculosis and carbapenem-resistant Enterobacteriaceae; halicin treated C. difficile and pan-resistant A. baumannii infections in mice. Of 23 tested predictions from over 107 million ZINC15 molecules, eight were antibacterial.
  • Still unknown: Human safety and efficacy are not reported in the abstract.
  • AI role: A deep neural network predicted antibacterial activity across chemical libraries; candidates were then tested experimentally.

Evidence sources: https://doi.org/10.1016/j.cell.2020.01.021

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review date: 16 Nov 2026. Review scope: Original institutional announcement checked for the specific results, AI contribution and limitations cited in the antibiotic dossier or mathematical follow-up pilot. Full-paper reanalysis, external replication and an exhaustive follow-up search were not performed..

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 2730 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 4/5 · Validation 3/5 · Novelty 5/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships
  • same-team extension · 25 May 2023: MIT describes abaucin as a subsequent application of the antibiotic-screening program to A. baumannii. This is a different candidate and target-specific study, not replication of halicin. Source. Recorded 16 Nov 2026.
  • same-team extension · 14 Aug 2025: MIT identifies halicin and abaucin as earlier screening results motivating generative design of new NG1/DN1 candidates. The later study does not establish clinical efficacy of these earlier candidates. Source. Recorded 16 Nov 2026.

Follow-up checked 16 Nov 2026 within scope: Bounded check of the original announcements cited by the events recorded here, including explicit links to later program work. This is not an exhaustive literature search or ongoing monitoring commitment..

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.